Adalgisa Condoluci

1.2k total citations
20 papers, 245 citations indexed

About

Adalgisa Condoluci is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Adalgisa Condoluci has authored 20 papers receiving a total of 245 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 13 papers in Pathology and Forensic Medicine and 5 papers in Molecular Biology. Recurrent topics in Adalgisa Condoluci's work include Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Adalgisa Condoluci is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Adalgisa Condoluci collaborates with scholars based in Switzerland, Italy and United States. Adalgisa Condoluci's co-authors include Davide Rossi, Aldo Pezzuto, Giuseppe Tonini, Calogero Mazzara, Alice Zoccoli, Pierfilippo Crucitti, Emanuele Zucca, Gaetano Rocco, Gianluca Gaïdano and Raffaele Rocco and has published in prestigious journals such as Blood, Leukemia and Frontiers in Oncology.

In The Last Decade

Adalgisa Condoluci

20 papers receiving 243 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adalgisa Condoluci Switzerland 10 106 96 74 48 47 20 245
Fabrice Jardin France 9 110 1.0× 61 0.6× 81 1.1× 50 1.0× 59 1.3× 22 277
Tove Wästerlid Sweden 9 176 1.7× 67 0.7× 121 1.6× 33 0.7× 31 0.7× 28 280
George Kanellis Greece 7 123 1.2× 83 0.9× 69 0.9× 42 0.9× 34 0.7× 18 214
Bertrand Filleul Belgium 8 65 0.6× 97 1.0× 69 0.9× 59 1.2× 84 1.8× 14 265
Erik Engel Germany 7 61 0.6× 66 0.7× 133 1.8× 54 1.1× 49 1.0× 14 232
Zsófia Balogh Hungary 9 80 0.8× 81 0.8× 58 0.8× 29 0.6× 31 0.7× 21 193
George P. Keogh United States 6 156 1.5× 177 1.8× 133 1.8× 33 0.7× 68 1.4× 10 323
Anna Wall United States 4 180 1.7× 53 0.6× 102 1.4× 29 0.6× 35 0.7× 7 225
Hun-Mo Ryoo South Korea 10 53 0.5× 42 0.4× 102 1.4× 106 2.2× 112 2.4× 30 300
Jonathan Lambert United Kingdom 9 74 0.7× 115 1.2× 61 0.8× 65 1.4× 24 0.5× 25 235

Countries citing papers authored by Adalgisa Condoluci

Since Specialization
Citations

This map shows the geographic impact of Adalgisa Condoluci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adalgisa Condoluci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adalgisa Condoluci more than expected).

Fields of papers citing papers by Adalgisa Condoluci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adalgisa Condoluci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adalgisa Condoluci. The network helps show where Adalgisa Condoluci may publish in the future.

Co-authorship network of co-authors of Adalgisa Condoluci

This figure shows the co-authorship network connecting the top 25 collaborators of Adalgisa Condoluci. A scholar is included among the top collaborators of Adalgisa Condoluci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adalgisa Condoluci. Adalgisa Condoluci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Condoluci, Adalgisa, Ilaria Romano, Daniel Dietrich, et al.. (2025). Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial. Blood. 145(22). 2587–2598. 2 indexed citations
2.
Pabst, Thomas, Marco M. Bühler, Adalgisa Condoluci, et al.. (2024). Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression. Annals of Hematology. 103(10). 4163–4170. 3 indexed citations
3.
Marchi, Francesco, Daniela Distefano, Lodovico Terzi di Bergamo, et al.. (2023). Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosis. Amyloid. 30(4). 416–423. 5 indexed citations
4.
Romano, Ilaria, Adalgisa Condoluci, & Davide Rossi. (2023). SOHO State of the Art Updates and Next Questions | Treatment of Richter's Transformation. Clinical Lymphoma Myeloma & Leukemia. 23(11). 786–799. 1 indexed citations
5.
Condoluci, Adalgisa & Davide Rossi. (2022). Biology and Treatment of Richter Transformation. Frontiers in Oncology. 12. 829983–829983. 29 indexed citations
6.
Condoluci, Adalgisa & Davide Rossi. (2021). Richter Syndrome. Current Oncology Reports. 23(3). 26–26. 14 indexed citations
7.
Baumann, Tycho, Riccardo Moia, Gianluca Gaïdano, et al.. (2021). Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. Leukemia. 35(8). 2325–2331. 10 indexed citations
8.
Condoluci, Adalgisa, Lorenzo Alberio, Jan–Dirk Studt, et al.. (2021). Thrombotic storm under DOAC treatment in a patient with homozygous antithrombin Budapest III mutation. Thrombosis Research. 201. 161–163. 2 indexed citations
9.
Condoluci, Adalgisa & Davide Rossi. (2021). Genomic Instability and Clonal Evolution in Chronic Lymphocytic Leukemia: Clinical Relevance. Journal of the National Comprehensive Cancer Network. 19(2). 227–233. 6 indexed citations
10.
Bruscaggin, Alessio, Lodovico Terzi di Bergamo, Valeria Spina, et al.. (2021). Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. Blood Advances. 5(22). 4674–4685. 17 indexed citations
11.
Condoluci, Adalgisa & Davide Rossi. (2020). SOHO State of the Art Updates and Next Questions: Clonal Evolution in Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 20(12). 779–784. 4 indexed citations
12.
Rossi, Davide, Mazyar Shadman, Adalgisa Condoluci, et al.. (2020). How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS‐CoV‐2 Pandemic. HemaSphere. 4(4). e432–e432. 14 indexed citations
13.
Condoluci, Adalgisa & Davide Rossi. (2019). The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas. Current Opinion in Hematology. 26(4). 281–287. 12 indexed citations
14.
Condoluci, Adalgisa & Davide Rossi. (2019). Clonal Evolution in Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 19. S16–S19. 1 indexed citations
15.
Condoluci, Adalgisa & Davide Rossi. (2019). Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment. Expert Review of Hematology. 12(2). 89–98. 7 indexed citations
16.
Rossi, Davide, Adalgisa Condoluci, Valeria Spina, & Gianluca Gaïdano. (2018). Methods for Measuring ctDNA in Lymphomas. Methods in molecular biology. 1881. 253–265. 9 indexed citations
17.
Condoluci, Adalgisa, Davide Rossi, Emanuele Zucca, & Franco Cavalli. (2018). Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma. Current Oncology Reports. 20(10). 79–79. 11 indexed citations
18.
Condoluci, Adalgisa & Davide Rossi. (2017). Treatment of Richter’s Syndrome. Current Treatment Options in Oncology. 18(12). 75–75. 13 indexed citations
19.
Crucitti, Pierfilippo, Giuseppe Mangiameli, Tommasangelo Petitti, et al.. (2016). Does prophylactic ligation of the thoracic duct reduce chylothorax rates in patients undergoing oesophagectomy? A systematic review and meta-analysis. European Journal of Cardio-Thoracic Surgery. 50(6). 1019–1024. 34 indexed citations
20.
Condoluci, Adalgisa, Calogero Mazzara, Alice Zoccoli, Aldo Pezzuto, & Giuseppe Tonini. (2016). Impact of Smoking on Lung Cancer Treatment Effectiveness: A Review. Future Oncology. 12(18). 2149–2161. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fabrice Jardin Breakdown of academic impact, for papers by Tove Wästerlid Breakdown of academic impact, for papers by George Kanellis Breakdown of academic impact, for papers by Bertrand Filleul Breakdown of academic impact, for papers by Erik Engel Breakdown of academic impact, for papers by Zsófia Balogh Breakdown of academic impact, for papers by George P. Keogh Breakdown of academic impact, for papers by Anna Wall Breakdown of academic impact, for papers by Hun-Mo Ryoo Breakdown of academic impact, for papers by Jonathan Lambert
Rankless by CCL
2026